2025-10-24 - Analysis Report
Okay, here's an analysis of Hims & Hers Health Inc (HIMS) based on the data you provided, presented in a report format with an English summary followed by more detailed analysis:

## Hims & Hers Health Inc (HIMS) Stock Analysis

**Hims & Hers Health Inc (HIMS) is a telehealth company that provides personalized health and wellness solutions.**

### 1. Performance vs. S&P 500 (VOO)

*   **HIMS Cumulative Return:** 223.67%
*   **VOO Cumulative Return:** 73.05%
*   **Absolute Divergence:** 154.1
*   **Relative Divergence:** 58.9 (Indicates HIMS is currently positioned at the 58.9th percentile of its historical divergence range from VOO).

**Summary:** HIMS has significantly outperformed the S&P 500 (VOO) over the period. The relative divergence suggests that while the outperformance is substantial, it is not at the extreme upper end of its historical range.

### 2. Alpha, Beta Analysis

| Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
|------------|---------|-------|--------|------|--------|
| 2019-2021  | -42.0%  | 74.4% | -81.0% | 0.0  | 1.4    |
| 2020-2022  | -19.0%  | 78.6% | -18.0% | -0.0 | 1.4    |
| 2021-2023  | -65.0%  | 78.6% | -67.0% | -0.1 | 1.9    |
| 2022-2024  | 119.0%  | 79.4% | 98.0%  | -0.0 | 5.2    |
| 2023-2025  | 228.0%  | 80.8% | 165.0% | 0.1  | 10.7   |

**Analysis:**

*   **CAGR:** Shows highly variable growth over different periods, with significant negative growth initially and then very strong growth in the later periods.
*   **MDD:** Maximum Drawdown remains consistently high, indicating significant volatility.
*   **Alpha:**  Initially negative, indicating underperformance relative to the benchmark.  The recent periods show very high positive alpha, suggesting strong outperformance.
*   **Beta:**  Fluctuates around zero or is slightly negative, suggesting HIMS's price movements are not strongly correlated with the overall market (VOO).
*   **Cap(B):** Market Cap is steadily growing

### 3. Recent Price Action

*   **Current Price:** 49.36
*   **Last Market Close:** Price: 48.49, Previous Close: 47.46, Change: 2.17
*   **5-Day Moving Average:** 54.48
*   **20-Day Moving Average:** 55.41
*   **60-Day Moving Average:** 52.21

**Analysis:** The stock price is below its 5-day, 20-day, and 60-day moving averages, suggesting a potential short-term downtrend. The recent price increase from 47.46 to 48.49 indicates a rebound from the previous trading day.

### 4. Market Risk Indicators & Signals

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 42.02 (Neutral)
*   **PPO:** -1.73 (Below zero, indicates bearish momentum)
*   **Hybrid Signal:** "Cash_0%_Buy 100% of cash" (Suggests a strong buy signal based on the model).
*   **Delta_Previous_Relative_Divergence:** -7.9 (Negative, indicates short-term decline relative to the benchmark)
*   **Expected Return:** 4.3% (Long-term expected excess return over S&P 500).

**Analysis:**

*   The high MRI suggests the market conditions are conducive to investment.
*   The RSI is neutral, not indicating overbought or oversold conditions.
*   The negative PPO suggests short-term bearish momentum.
*   The hybrid signal gives a strong buy signal.
*   The negative relative divergence change suggests short-term underperformance.
*   The expected return is positive, indicating potential long-term outperformance.

### 5. Recent News & Events

*   **Positive:** Mentions in lists of promising AI companies, bull case theories, and advancements in AI-powered healthcare.
*   **Negative:** Mention of the stock dipping more than the broader market and broader market
*   **Neutral:** Wall Street evaluation of Grail's cancer test results.

**Analysis:** The news is mixed, with some positive articles highlighting HIMS's potential in AI-driven healthcare, while others note recent price dips.

### 6. Analyst Opinions

*   **Consensus:** Hold (Mean: 2.93)
*   **Target Price:** Avg: 47.77, High: 85.00, Low: 25.00

**Analysis:**  Analysts, on average, have a "Hold" rating on the stock. The wide range in target prices suggests uncertainty about the stock's future performance.

### 7. Earnings Analysis

| 날짜       | EPS  | 매출    |
|------------|------|---------|
| 2025-08-04 | 0.19 | 0.54 B$ |
| 2025-05-05 | 0.22 | 0.59 B$ |
| 2024-11-04 | 0.35 | 0.40 B$ |
| 2024-08-05 | 0.06 | 0.32 B$ |
| 2025-08-04 | 0.06 | 0.32 B$ |

**Analysis:** The EPS is fluctuating, with the highest value of 0.35 in 2024-11-04 and the lowest value of 0.06 in 2024-08-05. Revenue is generally increasing.

### 8. Financial Information

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.54B  | 76.39%        |
| 2025-03-31 | $0.59B  | 73.50%        |
| 2024-12-31 | $0.48B  | 76.81%        |
| 2024-09-30 | $0.40B  | 79.16%        |
| 2024-06-30 | $0.32B  | 81.30%        |

| Quarter    | Equity  | ROE     |
|------------|---------|---------|
| 2025-06-30 | $0.56B  | 7.55%   |
| 2025-03-31 | $0.55B  | 9.01%   |
| 2024-12-31 | $0.48B  | 5.46%   |
| 2024-09-30 | $0.44B  | 17.18%  |
| 2024-06-30 | $0.36B  | 3.67%   |

**Analysis:**

*   **Revenue:**  Shows a generally increasing trend.
*   **Profit Margin:** Remains consistently high, indicating strong pricing power or efficient cost management.
*   **Equity:** Growing steadily.
*   **ROE:** Varies significantly, but generally positive, indicating profitability for shareholders.

### 9. Overall Assessment

Hims & Hers Health Inc (HIMS) presents a mixed picture.

**Positives:**

*   Significant outperformance compared to the S&P 500 in the past.
*   Strong revenue growth and high-profit margins.
*   Increasing equity.
*   Potential for long-term outperformance (positive expected return).
*   Strong "Buy" signal from the Hybrid Signal model.
*   Recent news highlighting the company's AI advancements.
*   Market conditions favor investment (high MRI).

**Negatives/Concerns:**

*   High historical volatility (high MDD).
*   Recent underperformance (negative PPO and relative divergence change).
*   "Hold" consensus from analysts and a wide range of target prices, suggesting uncertainty.
*   Stock price below key moving averages.
*   Fluctuating EPS.

**Conclusion:**

HIMS appears to be a growth company with significant potential, particularly in the telehealth and AI-driven healthcare space. However, it comes with considerable volatility and uncertainty. The recent dip and analyst skepticism warrant caution.

**Recommendation:**

*   **For long-term investors:** HIMS could be a worthwhile addition to a diversified portfolio, given its growth potential. However, be prepared for volatility. The Hybrid signal gives a strong buy signal, suggesting that now may be a good time to initiate or add to a position.
*   **For short-term traders:** The stock is currently in a downtrend, so caution is advised. Monitor the price action and moving averages for potential reversal signals.

This analysis is based on the limited data provided and should not be considered financial advice. Consult with a financial professional before making any investment decisions.
